Ongoing Clinical Trials for Extensive-Stage Small Cell Lung Cancer

Extensive-stage small cell lung cancer is an aggressive form of lung cancer that spreads rapidly throughout the body. Currently, 19 clinical trials are investigating new treatment combinations and approaches across Europe, including immunotherapies, targeted therapies, and innovative chemotherapy regimens. These studies aim to improve survival rates and quality of life for patients with this challenging disease.

Clinical trial locations

Study Comparing BMS-986489 with Chemotherapy to Atezolizumab with Chemotherapy for First-Line Treatment in Patients with Extensive-Stage Small Cell Lung Cancer

This trial is comparing two different treatment approaches for patients who have not yet received treatment for their extensive-stage disease. The study involves two groups: one receiving BMS-986489 (a combination of BMS-986012 and nivolumab) together with carboplatin and etoposide chemotherapy, while the other receives atezolizumab with the same chemotherapy drugs.

Main inclusion criteria: Participants must have a confirmed diagnosis of extensive-stage disease and be able to perform daily activities with little or no assistance. At least one tumor must be measurable using CT or MRI scans. Previous treatment for this type of cancer is not allowed, ensuring all participants are receiving their first line of therapy.

Main exclusion criteria: Patients with other types of cancer, those who have not fully recovered from previous treatments, individuals with severe heart problems or uncontrolled infections, and pregnant or breastfeeding women cannot participate. The trial also excludes those with symptomatic brain metastases.

Focus and goal: The primary goal is to determine whether BMS-986489 combined with chemotherapy helps patients live longer compared to atezolizumab with chemotherapy. The study will also monitor how long it takes for symptoms to worsen, treatment safety, and how well tumors respond to each approach.

Investigational drugs: BMS-986489 is a fixed-dose combination immunotherapy being tested alongside standard chemotherapy drugs carboplatin and etoposide. The comparator arm uses atezolizumab, an established immunotherapy, with the same chemotherapy regimen.

Study Comparing Sacituzumab Govitecan and Standard Treatment for Patients with Previously Treated Extensive Stage Small Cell Lung Cancer

This study is evaluating sacituzumab govitecan, an antibody-drug conjugate, for patients whose cancer has progressed after initial treatment. The trial compares this new medication to standard treatments currently used for previously treated disease.

Main inclusion criteria: Participants must have confirmed small cell lung cancer and an ECOG performance status of 0 or 1, meaning they can carry out most daily activities. The cancer must be measurable by CT or MRI, and patients must have documentation showing the disease worsened after at least one previous platinum-containing chemotherapy treatment.

Main exclusion criteria: Patients who have not recovered from previous cancer treatments, those with severe heart problems, uncontrolled infections, symptomatic brain metastases, or those who are pregnant or breastfeeding cannot participate. Recent participation in other investigational drug trials is also excluded.

Focus and goal: The primary objective is to determine whether sacituzumab govitecan improves outcomes compared to standard treatment options. The study measures how long patients live, how long they live without cancer progression, and monitors treatment safety and tumor response.

Investigational drugs: Sacituzumab govitecan is an antibody-drug conjugate that combines an antibody targeting cancer cells with a chemotherapy drug, allowing for more precise delivery of treatment directly to tumors.

Study for Patients with Lung or Urinary Tract Cancer Continuing Treatment with Durvalumab, Infliximab, and Mycophenolate Mofetil

This continuation study allows patients who participated in previous trials with durvalumab and are still benefiting from treatment to continue receiving the medication. The study also includes infliximab and mycophenolate mofetil as needed.

Main inclusion criteria: Patients must be currently benefiting from durvalumab treatment in a previous study and be eligible to continue receiving a fixed dose of 1500 mg every four weeks. A signed informed consent form is required.

Main exclusion criteria: Patients with medical conditions that could interfere with the study treatment, those unable to follow study procedures, pregnant or breastfeeding women, and individuals with severe allergies to the study medications cannot participate.

Focus and goal: The study aims to provide continued access to durvalumab for patients who are benefiting from it, while monitoring safety and tolerability. Serious adverse events are tracked for up to 90 days after the last dose.

Investigational drugs: Durvalumab is an immunotherapy that helps the immune system recognize and attack cancer cells by blocking a protein that prevents immune system activation. It is given as a fixed dose every four weeks.

Study of BMS-986012, carboplatin, etoposide and nivolumab combination as first treatment for patients with extensive-stage small cell lung cancer

This study evaluates a four-medication combination as first-line therapy, testing whether adding BMS-986012 to standard chemotherapy and nivolumab improves treatment outcomes.

Main inclusion criteria: Participants must be adults aged 18 or older with good physical condition (ECOG performance status of 0 or 1). At least one tumor must be measurable by CT or MRI, and patients must have adequate blood cell counts and proper organ function. Effective birth control is required during the study.

Main exclusion criteria: Previous anti-cancer therapy for extensive-stage disease, active brain metastases or spinal cord compression, other cancers within the last 3 years, active infections including hepatitis B/C or HIV, serious heart conditions in the past 6 months, and active autoimmune disease requiring treatment are all exclusion criteria.

Focus and goal: The study aims to assess the safety and effectiveness of combining BMS-986012 with carboplatin, etoposide, and nivolumab. Treatment begins with four cycles of all medications together, followed by maintenance therapy with BMS-986012 and nivolumab.

Investigational drugs: BMS-986012 is an experimental antibody being combined with nivolumab (an immunotherapy), carboplatin, and etoposide (both chemotherapy drugs). The combination approach targets cancer through multiple mechanisms.

Study of Lurbinectedin and Atezolizumab for Maintenance Therapy in Patients with Extensive-Stage Small-Cell Lung Cancer

This maintenance therapy trial tests whether adding lurbinectedin to atezolizumab after initial treatment can help keep cancer from returning or progressing.

Main inclusion criteria: Patients must have confirmed small cell lung cancer with adequate organ function and an ECOG performance status of 0 or 1. They must have received initial treatment with atezolizumab, carboplatin, and etoposide with ongoing response or stable disease. Any side effects from previous treatments must have improved to mild levels.

Main exclusion criteria: Patients with other types of cancer, those outside the specified age range, individuals unable to follow study procedures, pregnant or breastfeeding women, and those with allergies to study medications cannot participate.

Focus and goal: The primary goal is to compare progression-free survival between patients receiving lurbinectedin plus atezolizumab versus atezolizumab alone as maintenance therapy. The study monitors how long patients live without cancer progression and overall survival rates.

Investigational drugs: Lurbinectedin is a DNA-binding agent being tested in combination with atezolizumab, an immune checkpoint inhibitor. Both are given as intravenous infusions following initial chemotherapy treatment.

Study on Maintenance Therapy with Durvalumab and Olaparib for Patients with Extensive Disease Small-Cell Lung Cancer

This German trial evaluates the combination of durvalumab and olaparib as maintenance therapy for patients with certain genetic characteristics after completing initial treatment.

Main inclusion criteria: Participants must be at least 18 years old with advanced or metastatic disease that cannot be treated with surgery or radiation. They must have a positive test for homologous recombination deficiency (HRD), an ECOG performance status of 0 or 1, weigh more than 30 kg, and have completed four cycles of chemotherapy with carboplatin or cisplatin, etoposide, and durvalumab without cancer progression.

Main exclusion criteria: Patients with other types of cancer, recent participation in other trials, serious health conditions that could interfere with treatment, pregnancy or breastfeeding, and inability to follow study procedures are excluded.

Focus and goal: The study evaluates whether combining olaparib with durvalumab as maintenance therapy improves progression-free survival in patients with specific genetic mutations. Regular monitoring assesses treatment effectiveness and safety.

Investigational drugs: Olaparib is a PARP inhibitor taken orally that targets cancer cells with specific DNA repair defects. Durvalumab is an immunotherapy given intravenously that helps the immune system fight cancer by blocking the PD-L1 protein.

Study on Niraparib with Immunotherapy for Patients with SLFN11-Positive Extensive-Stage Small Cell Lung Cancer

This study examines whether adding niraparib to anti-PD-L1 antibody maintenance therapy benefits patients whose tumors show high levels of the SLFN11 protein.

Main inclusion criteria: Patients must have extensive-disease small cell lung cancer with high SLFN11 expression confirmed by a specialized laboratory. They must have completed standard first-line treatment with four cycles of platinum-etoposide chemotherapy and an anti-PD-L1 antibody without cancer progression, have normal organ function, an ECOG performance status of 0-2, and be at least 18 years old.

Main exclusion criteria: Patients without high SLFN11 expression or those whose cancer progressed after standard first-line treatment cannot participate.

Focus and goal: The primary objective is to assess the proportion of participants who are alive and progression-free at 3 months. The study also evaluates overall survival, disease control rates, and treatment safety.

Investigational drugs: Niraparib is a PARP inhibitor taken orally that works by preventing cancer cells from repairing DNA damage. It is combined with anti-PD-L1 antibody maintenance therapy (either atezolizumab or durvalumab).

Study on the Effectiveness and Safety of Pembrolizumab, Quavonlimab, and Lenvatinib for Patients with Advanced Small Cell Lung Cancer Needing Second-Line Treatment

This trial evaluates several investigational treatment combinations for patients requiring second-line therapy after their cancer progressed on initial treatment.

Main inclusion criteria: Participants must have confirmed extensive-stage disease requiring second-line therapy, provide tumor tissue samples, have an ECOG performance status of 0 or 1, a life expectancy greater than 3 months, and have experienced cancer progression after treatment with anti-PD-1/PD-L1 antibodies. Well-controlled blood pressure and adequate organ function are required.

Main exclusion criteria: Patients outside the specified age range or those belonging to vulnerable populations requiring special protection cannot participate.

Focus and goal: The study evaluates the safety and effectiveness of pembrolizumab combined with other investigational agents including quavonlimab, favezelimab, MK-4830, and lenvatinib. The trial monitors treatment response and side effects.

Investigational drugs: Pembrolizumab is an immune checkpoint inhibitor that blocks a protein allowing the immune system to better attack cancer cells. It is tested in combination with other investigational immunotherapy and targeted therapy agents.

Study on Trilaciclib and Topotecan for Patients with Extensive Stage Small Cell Lung Cancer

This study evaluates whether trilaciclib can protect bone marrow from chemotherapy damage and improve survival when given before topotecan chemotherapy.

Main inclusion criteria: Participants must be at least 18 years old with an ECOG performance status of 0-2, adequate organ function, and resolved side effects from previous treatments. They must have confirmed extensive-stage disease with documented progression during or after previous platinum-containing chemotherapy and be eligible to receive topotecan.

Main exclusion criteria: Patients who have not recovered from previous treatments or those outside the specified age range cannot participate.

Focus and goal: The primary objective is to determine whether trilaciclib improves overall survival compared to placebo when given before topotecan chemotherapy. The study also evaluates cancer response and side effects.

Investigational drugs: Trilaciclib is a cyclin-dependent kinase 4/6 inhibitor designed to protect bone marrow from chemotherapy damage. Topotecan is a chemotherapy drug that stops cancer cells from growing and dividing.

Study of Durvalumab, Cisplatin, Carboplatin, and Etoposide for Patients with Extensive Stage Small Cell Lung Cancer

This German study tests a treatment plan combining chemotherapy, radiotherapy, and immunotherapy to improve patient outcomes.

Main inclusion criteria: Participants must have a first diagnosis of extensive-stage disease confirmed by tissue testing, oligometastatic disease (primary tumor with up to four distant lesions treatable with specialized radiation), stable disease or partial response after two cycles of platinum/etoposide/durvalumab chemotherapy, an ECOG performance status of 0 or 1, and a life expectancy of at least 12 weeks.

Main exclusion criteria: Patients with other types of cancer, those who had previous interfering treatments, serious health conditions making treatment unsafe, pregnancy or breastfeeding, inability to follow procedures, known allergies to study drugs, or current participation in another trial are excluded.

Focus and goal: The study evaluates feasibility and effectiveness of combining chemotherapy with thoracic radiotherapy, followed by stereotactic radiotherapy and maintenance durvalumab. The primary measure is progression-free survival at 12 months.

Investigational drugs: The treatment combines durvalumab (immunotherapy), cisplatin or carboplatin (platinum-based chemotherapy), and etoposide (chemotherapy) with radiotherapy approaches.

Study of Ifinatamab Deruxtecan with Atezolizumab and Carboplatin for Patients with Extensive-Stage Small Cell Lung Cancer

This trial evaluates ifinatamab deruxtecan, an antibody-drug conjugate, combined with atezolizumab and carboplatin as first-line treatment.

Main inclusion criteria: Participants must sign informed consent, be at least 18 years old, have confirmed extensive-stage disease, at least one measurable tumor by CT or MRI, adequate organ function, an ECOG performance status of 0 or 1, and a life expectancy of at least 3 months. Patients must agree to provide tumor tissue samples and use effective contraception.

Main exclusion criteria: Patients with other cancer types, those outside the age range, individuals unable to safely receive study treatments, pregnant or breastfeeding women, and those with medical conditions interfering with treatment cannot participate.

Focus and goal: The study assesses safety and tolerability of ifinatamab deruxtecan combined with atezolizumab, with or without carboplatin. Regular monitoring evaluates treatment response, progression-free survival, and overall survival.

Investigational drugs: Ifinatamab deruxtecan is an antibody-drug conjugate targeting the B7-H3 protein on cancer cells. Atezolizumab is an immunotherapy blocking PD-L1. Carboplatin is a platinum-based chemotherapy drug. All are administered intravenously.

Summary

The 19 ongoing clinical trials for extensive-stage small cell lung cancer represent a diverse research effort across Europe, with particular concentration in countries like Germany, Spain, Italy, France, and Poland. Most trials focus on first-line treatment approaches, combining immunotherapies like durvalumab, atezolizumab, nivolumab, and pembrolizumab with traditional chemotherapy regimens. Several studies explore maintenance therapy strategies after initial treatment response, recognizing the aggressive nature of this disease.

Notable trends include the investigation of antibody-drug conjugates such as sacituzumab govitecan and ifinatamab deruxtecan, which offer more targeted treatment approaches. Multiple trials examine novel immunotherapy combinations and explore biomarker-driven strategies, particularly focusing on patients with specific genetic characteristics like SLFN11 expression or homologous recombination deficiency. The diversity of treatment approaches reflects ongoing efforts to improve outcomes for this challenging disease through personalized medicine strategies.

Most trials require participants to have good performance status and adequate organ function, emphasizing the importance of overall health in tolerating these intensive treatment regimens. The geographic distribution of trials across multiple European countries provides broader access to experimental treatments for patients in various regions.

#1 Clinical Trials Search in Europe

Small cell lung cancer extensive stage – Trials in Disease

Ongoing Clinical Trials for Extensive-Stage Small Cell Lung Cancer

Clinical trial locations

Study Comparing BMS-986489 with Chemotherapy to Atezolizumab with Chemotherapy for First-Line Treatment in Patients with Extensive-Stage Small Cell Lung Cancer

Study Comparing Sacituzumab Govitecan and Standard Treatment for Patients with Previously Treated Extensive Stage Small Cell Lung Cancer

Study for Patients with Lung or Urinary Tract Cancer Continuing Treatment with Durvalumab, Infliximab, and Mycophenolate Mofetil

Study of BMS-986012, carboplatin, etoposide and nivolumab combination as first treatment for patients with extensive-stage small cell lung cancer

Study of Lurbinectedin and Atezolizumab for Maintenance Therapy in Patients with Extensive-Stage Small-Cell Lung Cancer

Study on Maintenance Therapy with Durvalumab and Olaparib for Patients with Extensive Disease Small-Cell Lung Cancer

Study on Niraparib with Immunotherapy for Patients with SLFN11-Positive Extensive-Stage Small Cell Lung Cancer

Study on the Effectiveness and Safety of Pembrolizumab, Quavonlimab, and Lenvatinib for Patients with Advanced Small Cell Lung Cancer Needing Second-Line Treatment

Study on Trilaciclib and Topotecan for Patients with Extensive Stage Small Cell Lung Cancer

Study of Durvalumab, Cisplatin, Carboplatin, and Etoposide for Patients with Extensive Stage Small Cell Lung Cancer

Study of Ifinatamab Deruxtecan with Atezolizumab and Carboplatin for Patients with Extensive-Stage Small Cell Lung Cancer

Summary

Ongoing Clinical Trials on Small cell lung cancer extensive stage

Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer

Testing Tarlatamab in Patients with Advanced Small-Cell Lung Cancer Who Have Poor Physical Condition

Study of tarlatamab with durvalumab, carboplatin and etoposide versus standard treatment in patients with previously untreated extensive stage small cell lung cancer

Study Comparing Sacituzumab Govitecan and Standard Treatment for Patients with Previously Treated Extensive Stage Small Cell Lung Cancer

Study Comparing BMS-986489 with Chemotherapy to Atezolizumab with Chemotherapy for First-Line Treatment in Patients with Extensive-Stage Small Cell Lung Cancer

Study of Ifinatamab Deruxtecan with Atezolizumab and Carboplatin for Patients with Extensive-Stage Small Cell Lung Cancer

Study on Niraparib with Immunotherapy for Patients with SLFN11-Positive Extensive-Stage Small Cell Lung Cancer

Study on Pembrolizumab and Olaparib for Patients with Extensive-Stage Small-Cell Lung Cancer

Study on Durvalumab with Carboplatin or Cisplatin and Etoposide for First-Line Treatment in Patients with Extensive Stage Extrapulmonary Small Cell Carcinoma

Study on Trilaciclib and Topotecan for Patients with Extensive Stage Small Cell Lung Cancer

Connected medications:

Small cell lung cancer extensive stage – Trials in Disease

Ongoing Clinical Trials for Extensive-Stage Small Cell Lung Cancer

Clinical trial locations

Summary

Ongoing Clinical Trials on Small cell lung cancer extensive stage

More information aboutSmall cell lung cancer extensive stage:

Connected medications:

We use cookies

More information about
Small cell lung cancer extensive stage: